Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 31st Preview)
-
ASCO late-stage oncology highlights
Revolution Medicines delivered what oncologists described as “landscape-changing” data for daraxonrasib at ASCO, extending survival in second-line metastatic pancreatic cancer with RAS-pathway–driven tumors. In the Phase 3 trial, daraxonrasib nearly doubled median survival versus standard chemotherapy, with fuller ASCO details indicating a median 13.2-month survival across the full study population. The study focused on patients whose disease progressed after prior treatment and whose tumors were driven by a RAS G12 mutation, while also evaluating outcomes in broader groups. Across all daraxonrasib-treated recipients, investigators reported median survival of 13.2 months versus 6.6 months with chemotherapy in the RAS G12 subgroup and similar outcomes across the all-comer population. Revolution also highlighted durable disease control: median progression-free timeframes roughly doubled compared with chemotherapy, and early safety signals were framed as consistent with an “expected safety profile.” Multiple investigators pointed to rapid patient-reported improvements, including pain and tumor marker responses, following initiation. Separate ASCO coverage reinforced the intensity of the immunotherapy race in China, where Akeso and Summit’s ivonescimab showed a 34% reduction in risk of death in previously untreated Chinese patients with squamous non-small cell lung cancer, published alongside the clinical readout in The Lancet.
-
Immuno-oncology trial readout in NSCLC
Akeso and Summit’s ivonescimab extended survival in a China-based Phase 3 study in previously untreated squamous NSCLC, delivering a 34% risk reduction in death versus standard immunotherapy plus chemotherapy. The results were presented at ASCO and published simultaneously in The Lancet. Ivonescimab is a PD-1/VEGF-targeting bispecific designed to combine checkpoint blockade with anti-angiogenic activity. In the trial conducted entirely in China, the companies framed the outcome as exceeding expectations, while the readout is likely to intensify scrutiny around how China-only evidence will translate into global development strategies. Summit positioned the asset as an early-stage commercial opportunity, with co-CEO Robert Duggan citing the data as indication of “a very valuable business” for a program moving outside China. The broader takeaway for the field is that competitive differentiation in next-generation bispecifics remains tightly linked to overall survival choices and study design. The pairing of Akeso’s China execution and Summit’s planned expansion outside China is likely to be closely watched as regulators and clinicians weigh whether similar magnitude of benefit can be reproduced in multinational trials.
-
FDA and US regulatory direction
FDA user-fee negotiations for the next cycle moved into White House review, according to sources describing scrutiny of a deal that sets prescription drug user fees for 2028 through 2032. The process underscores how tightly the schedule and the final numbers are tied to broader federal decision-making. The user-fee framework typically influences resourcing and review timelines across the agency, which is especially relevant as oncology and gene therapies compete for efficient regulatory throughput. Industry analysts have also linked user-fee cycles to incentives for early engagement and review capacity. With the White House examining the agreement, the next steps are expected to shape timelines for the pharmaceutical industry’s planning around submissions and planned label expansions. Separately, Rick Pazdur told ASCO attendees that recent turmoil has opened space for FDA restructuring, emphasizing that the agency could rebuild staffing and administrative structure rather than restore the status quo.
-
Next FDA label expansion watchlist
FDA is set for a busy June with 11 upcoming PDUFA dates, including a late-month decision that could expand the label of Ionis Pharmaceuticals’ Tryngolza olezarsen. The antisense oligonucleotide currently approved for familial chylomicronemia syndrome is being considered for expansion into severe hypertriglyceridemia, which would broaden market reach substantially. The PDUFA calendar also signals continued momentum in nucleic-acid therapeutics, as regulators weigh safety and efficacy for new indications. For biotech and pharma, the sequence of decisions in June provides a near-term window into pricing, access, and competitive positioning for lipid-lowering platforms. Ionis’ development program, which targets APOC3 via an antisense approach, is one of the highest-profile agenda items amid competing lipid therapies and evolving benefit design. Overall, the combination of a concentrated PDUFA slate and potential indication expansion means near-term outcomes could shift both pipeline expectations and commercial forecasting across the category.
-
Big pharma-foreign biotech deal for ADCs
Pfizer and Innovent Biologics inked an up-to-$10.5 billion global licensing and collaboration agreement covering 12 early-stage and de novo antibody and ADC programs, marking another major move by big pharma to draw from China-based innovation pipelines. The deal includes co-development and co-commercialization plans for selected assets as they advance through clinical development. Innovent will contribute eight programs originating with the Chinese biotech, while Pfizer brings four discovery-stage programs. The companies said the ADCs and bispecifics will be designed to differentiate via payload and immune-engaging features. Pfizer framed the collaboration as a way to strengthen its oncology pipeline as companies race to offset patent expiries and build successor franchises. For Innovent, the upfront structure and global-scale partnership provides resources for later-stage execution and regulatory strategy. The breadth of the portfolio—covering both ADCs and multispecific antibodies—suggests the partnership is aimed at building multiple shots on goal across cancer types, rather than a single lead asset.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.